On Thursday, Alpha MOS reported a "positive" outlook for fiscal 2024, boosted by the deployment of its technologies with key accounts and the launch of new applications, causing its share price to rise by over 3%.

The sensory analysis specialist reports that its consolidated sales fell by 22% last year, to 4.5 million euros.

Its operating loss deteriorated accordingly, to over 3.8 million euros for the year, compared with 2.4 million in 2022, while its net loss widened to 4.7 million euros, after 2.7 million the previous year.

In its press release, the industrial nose manufacturer says it is counting on expanding its range of products and services, as well as improving its penetration of key accounts.

It explains that trends in the agri-food market are indeed moving in the direction of greater use of instruments, data and artificial intelligence tools.

In medical technology ('medtech'), Alpha MOS, through its subsidiary BoydSense, plans to pursue the development of its breath biomarker analysis product, with a view to finalizing a marketable product.

Copyright (c) 2024 CercleFinance.com. All rights reserved.